 |
 |
|
|
Grouped together on the same campus the university team EMR 3738 Chemotherapeutic Targeting in Oncology, the medical oncology ward of South Lyon Hospital and the department of biochemistry make up the HCL/UCBL platform of Phase I trials. Linked to the Thematic network on Research and Treatment “Synergie Lyon Cancer”, these three entities have the complementary skills necessary to carry out clinical studies of antineoplastic agents, particularly at the time of Phase I studies.
 |
ClinicalThe clinical side is managed by the professors Véronique Trillet-Lenoir and Gilles Freyer. Working alongside Professor Coiffier in the haematology department, this ward receives patients presenting with all solid and haematological tumours. The medical wards are connected to a Centralized Pharmacy Unit for Cytotoxic drugs Unit managed by Dr Catherine Rioufol. |
Biomathematical and PharmacologicalWithin the EMR 3738 university team managed by Professor Michel Tod, with a more fundamental focus on in silico pharmacokinetic-pharmacodynamic (PK-PD) modelling, they also work alongside the pharmaceutical industry during cancer drug development. |
 |
 |
AnalyticalThe analytical side is governed by the biochemistry laboratory where Professor Jérôme Guitton is responsible for dose development thanks to equipment acquired by the HCL especially for the Phase I trials and use of liquid chromatography tandem mass spectrometry (LC-MS/MS). |
Close links of the platform with the specialised biological investigation facilities as well as the structure of its clinical research committee guarantee the effectiveness of the recruitment and respect of the ethical standards (Good Clinical Practice), also allowing numerous partnerships. The pharmacology department, working closely with the biochemistry laboratory for the drug assay, is also involved in the preclinical and phase I development of new molecules. The complex numerical models created are subject to user agreements for data analysis. Software tools have also been developed to monitor chemotherapy in clinical practice.
The project to create this platform was built on many years of shared work. The close geographical partnership has allowed different members, medical oncologists, pharmacokineticists, biochemists and methodologists, to build a strong and permanent collaboration. Close relationships have been forged with researchers within INSERM (the national institute of medical research), INRIA and the Ecole des Mines in Saint Etienne, as well as teacher-researchers from the universities of Saint Etienne and Grenoble.
Besides the improvement in routine diagnostic practice and care as a result of their implication in innovation, the clinical services also actively participate in the clinical development of new molecules. Many international clinical trials leading to the registration of various molecules in Europe and the United States of America have been carried out in Lyon, including rituximab (Roche & Genentech), interferon (Schering Plough), oxaliplatine (Sanofi-Aventis), vinorelbine (Pierre Fabre Oncology) and inolimomab (Laboratoires Opi).
